Obesity Trial, Recruiting NCT07330297 Sponsor: I.M. Sechenov First Moscow State Medical University Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT07330297
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has three separate groups. People may be considered for one of the following:

Group 1 – Metabolic Syndrome:

  • Adults over 18 years old who have been diagnosed with Metabolic Syndrome, meaning a large waist measurement (over 94 cm for men, over 80 cm for women) plus at least two of the following: high blood pressure or taking blood pressure medication; high triglycerides (a type of fat in the blood); low "good" cholesterol (HDL); or higher-than-normal fasting blood sugar levels
  • People who have signed a form agreeing to take part in the study

Group 2 – Obesity without other metabolic problems:

  • Adults over 18 years old with a large waist measurement (94 cm or more for men, 80 cm or more for women), but who do not have high blood pressure, abnormal cholesterol levels, or raised fasting blood sugar
  • People who have signed a form agreeing to take part in the study

Group 3 – Control group:

  • Adults over 18 years old with a normal body weight and no signs of Metabolic Syndrome
  • People who have signed a form agreeing to take part in the study

Who may not be able to join:

  • People who are not able to give informed consent to participate
  • People who have previously had a heart attack or stroke
  • People with moderate-to-severe kidney disease (where the kidneys are working at a significantly reduced level)
  • People with an active or recent serious heart or blood vessel condition
  • People with a hereditary condition causing very high cholesterol (familial hypercholesterolaemia)
  • People with lung or airway diseases
  • People with active or recent infections, whether short-term or long-term
  • People with Type 1 or Type 2 diabetes
  • People with diseases affecting the body's connective tissues throughout the body (such as lupus or rheumatoid arthritis)
  • People with a current or past cancer diagnosis
  • People with severe liver disease or advanced liver failure
  • People who are pregnant or breastfeeding
  • People with a severe mental illness such as advanced dementia or schizophrenia
  • People with serious health conditions where life expectancy is estimated to be less than one year
  • People who are found, after joining the study, to meet any of the above criteria (confirm with trial site)
  • People who decide they no longer wish to continue participating after joining

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +7 (903) 687-72-64

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
I.M. Sechenov First Moscow State Medical University
Registry
ClinicalTrials.gov
Start date
19 September 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Specificity of the combined PTR-MS and machine learning model.; Sensitivity of the combined PTR-MS and machine learning model.; Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of the combined PTR-MS and machine learning model.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov